SCHEMBL22323905

SCHEMBL22323905

COc1ccc(COc2ccncc2Br)cc1

nearest known ligand 0.51

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.51
RAB9A P51151 2/20 0.51
LRRK2 Q5S007 1/20 0.47
APP P05067 5/20 0.45
MAOB P27338 2/20 0.44
ABCB1 P08183 1/20 0.43
IDO1 P14902 2/20 0.42
AGXT P21549 2/20 0.42
CYP17A1 P05093 1/20 0.42
TP53 P04637 1/20 0.41
MAPT P10636 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
POLB P06746 1/20 0.41
CSF1R P07333 2/20 0.41
NTRK1 P04629 1/20 0.41
NTRK3 Q16288 1/20 0.41
NTRK2 Q16620 1/20 0.41
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27037199 0.88 NPC1 (0.51) NPC1RAB9ALRRK2APPMAOB
SCHEMBL16019002 0.86 NPC1 (0.55) NPC1RAB9ALRRK2APPMAOB
SCHEMBL31013377 0.84 NPC1 (0.54) NPC1RAB9AAPPMAOBABCB1
SCHEMBL13410566 0.84 TBXAS1 (0.40) NPC1RAB9ALRRK2APPMAOB
SCHEMBL28694513 0.84 LRRK2 (0.40) NPC1RAB9ALRRK2CYP17A1TP53
SCHEMBL3606177 0.81 ABCB1 (0.50) RAB9ALRRK2ABCB1IDO1MAPT
SCHEMBL30452934 0.81 ABCB1 (0.50) RAB9ALRRK2ABCB1IDO1MAPT
SCHEMBL5515424 0.81 NPC1 (0.47) NPC1RAB9ALRRK2APPMAOB
SCHEMBL21840739 0.80 KDM4C (0.46) POLB
SCHEMBL30145233 0.78 ABCB1 (0.59) NPC1RAB9AAPPMAOBABCB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12509460-B2 Methods and compositions for modulating splicing SKYHAWK THERAPEUTICS, INC. (US) 2025-12-30 US disclosed
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. 2023-01-19 US disclosed
CN-114126613-A Methods and compositions for modulating splicing 斯基霍克疗法公司 2022-03-01 CN disclosed
EP-3920926-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING Skyhawk Therapeutics, Inc. (US) 2021-12-15 EP disclosed
WO-2020163541-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING SKYHAWK THERAPEUTICS, INC. (US) 2020-08-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230020922-A1 METHODS AND COMPOSITIONS FOR MODULATING SPLICING RBM17, SF3B1, SNRPA1 NPC1 2258/4885RAB9A 3071/4885LRRK2 2539/4885
US-12509460-B2 Methods and compositions for modulating splicing SF3B1, RTCB, RBM17 NPC1 1286/4885RAB9A 2285/4885LRRK2 2608/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.